New drug combo tested for aggressive blood cancer
NCT ID NCT05391750
Summary
This early-stage trial is testing the safety of combining two drugs—venetoclax and tocilizumab—for multiple myeloma that has returned or stopped responding to treatment. The study focuses on patients whose cancer has a specific genetic change called t(11;14). Researchers want to find the safest dose and understand side effects before testing whether this combination effectively controls the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.